CAPR — Capricor Therapeutics, Inc. stock price, charts and financials

QT34Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
3.87
-0.22-5.38%
OverviewShort InterestFilings
CAPRQT34Capricor Therapeutics, Inc.·NASDAQ
3.87-5.38%
Earnings
Down 5.4% — Earnings due 2026-08-11 — pre-report positioning.
Medium confidence
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
AUPH-2.33%$15.48MESO+4.96%$16.73ZBIO-1.46%$31.96GHRS-2.07%$29.64TSHA-0.69%$6.51STOK-1.46%$32.23ABCL+31.03%$9.08VRDN-2.29%$23.05
Snapshot
Index-P/E-EPS (ttm)-1.20Insider Own37.69%Shs Outstand57.51MPerf Week6.23%
Market Cap235.22MForward P/E-EPS next Y-1.25Insider Trans-1.24%Shs Float48.21MPerf Month-81.82%
Enterprise Value150.92MPEG0.04EPS next Q-Inst Own-Short Float32.31%Perf Quarter-87.95%
Income-114.74MP/S0.00EPS this Y3.00%Inst Trans-Short Ratio12.87Perf Half Y-82.24%
Sales22.00MP/B0.84EPS next Y-7.82%ROA-35.12%Short Interest15.58MPerf YTD-85.83%
Book/sh-P/C-EPS next 5Y-ROE-59.27%52W High38.20 -89.87%Perf Year-47.16%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-40.00%52W Low2.80 38.18%Perf 3Y-8.30%
Dividend Est.-EV/EBITDA0.17Sales past 3/5Y-Gross Margin0.00%Volatility11.42% 9.68%Perf 5Y-6.41%
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-4.35%Oper. Margin0.00%ATR (14)1.65Perf 10Y-89.03%
Dividend Ex-Date-Quick Ratio8.42Sales Y/Y TTM0.00%Profit Margin0.00%RSI (14)14.28Recom2.40
Dividend Gr. 3/5Y-Current Ratio8.42EPS Q/Q-11.32%SMA20-66.84%Beta0.40Target Price5.83
Payout0.00%Debt/Eq0.08Sales Q/Q-SMA50-80.18%Rel Volume1.29Prev Close4.09
Employees231LT Debt/Eq0.05EarningsAug 11SMA200-82.39%Avg Volume2.81MPrice3.87
IPO DateFeb 13, 2007Option/ShortYes / YesEPS/Sales Surpr.-16.26% -Net Debt/EBITDA-0.09Volume3,608,433Change-5.38%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-31-26DowngradeJones TradingBuy → Hold
Jul-30-26DowngradePiper SandlerOverweight → Neutral
Jul-30-26DowngradeHC Wainwright & Co.Buy → Neutral
Jul-30-26DowngradeCantor FitzgeraldOverweight → Neutral$3.50
Jul-28-26ReiteratedIndustrial Alliance Securities$7.00
Jul-27-26ReiteratedRoth CapitalBuy$7.00
May-15-26ReiteratedRoth CapitalBuy
Mar-13-26ReiteratedCantor FitzgeraldOverweight
Dec-15-25ReiteratedUBS
Dec-10-25ReiteratedPiper SandlerOverweight
Latest News
Today
Today09:56AM
CAPR EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 29, 2026newsfilecorp.com
08:26AM
Berger Montague PC Investigating Claims on Behalf of Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors After Class Action Filingprnewswire.com
08:22AM
CAPR Alert: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, September 28, 2026 Lead Plaintiff Deadlineprnewswire.com
08:15AM
Kaplan Fox & Kilsheimer LLP Alerts Capricor Therapeutics, Inc. (CAPR) Investors to a Securities Class Action Deadline on September 28, 2026newsfilecorp.com
06:46AM
Capricor Therapeutics (NASDAQ:CAPR) Securities Class Action Notice: Investors who Lost Money when Stock Plummeted 64% are Notified to Contact BFA Law by September 28globenewswire.com
05:58AM
Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPRprnewswire.com
04:52AM
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Lawprnewswire.com
Aug-09-26
Aug-09-2612:00PM
Bronstein, Gewirtz & Grossman LLC Urges Capricor Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harmglobenewswire.com
08:43AM
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CAPRnewsfilecorp.com
Aug-08-26
Aug-08-2612:35PM
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuitprnewswire.com
Aug-07-26
Aug-07-2604:10PM
Kaplan Fox Reminds Capricor Therapeutics, Inc. (CAPR) Investors of a Securities Class Action Deadline on September 28, 2026newsfilecorp.com
03:03PM
Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP Before Application Deadlineglobenewswire.com
02:42PM
Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadlinenewsfilecorp.com
11:10AM
INVESTOR NOTICE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit - CAPRprnewswire.com
10:20AM
Capricor Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Capricor Therapeutics, Inc. - CAPRglobenewswire.com
Company

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue22022——————
Cost of Goods Sold Incl. D&A51050——————
Gross Profit-280-28——————
Selling, General and Administrative Excl. Other142315——————
Research and Development518450——————
Other Operating Expense-511-50——————
Operating Income-43-108-43——————
Interest Expense030——————
Unusual Expense
—————————
Non-Operating Income (Expense)262——————
Net Income Before Taxes-41-105-40——————
Income Taxes
000——————
Consolidated Net Income-41-105-40——————
Net Income From Continuing Operations-41-105-40——————
Net Income-41-105-40——————
EPS (Recurring)-1.20-2.26-1.15——————
EPS (Basic, Before Extraordinaries)-1.20-2.26-1.15——————
EPS (Diluted)-1.20-2.26-1.15——————
EBITDA-39-100-39——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio6.16—21.95——————
Gross Margin-127.27—-127.27——————
Operating Margin-195.45—-195.45——————
Net Margin-186.36—-181.82——————
Shares Outstanding354635——————
Market Capitalization1351,328483——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$40.06$29.83$19.60$9.36$-0.87● Close Price0.00M0.84M1.68M2.52M3.35MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Bergmann AnthonyCHIEF FINANCIAL OFFICERJun 25 '26Option Exercise3.1824,10076,63835,323Jun 29
Krasney KarenEVP, GENERAL COUNSELJun 25 '26Sale30.3824,100732,15830,547Jun 29
Bergmann AnthonyCHIEF FINANCIAL OFFICERJun 25 '26Sale30.3824,100732,15811,223Jun 29
Krasney KarenEVP, GENERAL COUNSELJun 25 '26Option Exercise3.1824,10076,63854,647Jun 29
Bergmann AnthonyCHIEF FINANCIAL OFFICERJun 24 '26Sale30.0040012,00011,223Jun 24
Bergmann AnthonyCHIEF FINANCIAL OFFICERJun 24 '26Option Exercise3.184001,27211,623Jun 24
Krasney KarenEVP, GENERAL COUNSELJun 24 '26Option Exercise3.184001,27230,947Jun 24
Krasney KarenEVP, GENERAL COUNSELJun 24 '26Sale30.0040012,00030,547Jun 24
Krasney KarenEVP, GENERAL COUNSELJun 22 '26Option Exercise3.185001,59031,047Jun 24
Bergmann AnthonyCHIEF FINANCIAL OFFICERJun 22 '26Option Exercise3.185001,59011,723Jun 24
Bergmann AnthonyCHIEF FINANCIAL OFFICERMay 18 '26Option Exercise1.393,0004,17011,223May 19
Litvack FrankDirectorMay 13 '26Option Exercise1.393,9375,472133,776May 14
Bergmann AnthonyCHIEF FINANCIAL OFFICERMay 01 '26Option Exercise3.1825,00079,50033,223May 04
Bergmann AnthonyCHIEF FINANCIAL OFFICERMay 01 '26Sale31.7025,000792,5408,223May 04
Krasney KarenEVP, GENERAL COUNSELMay 01 '26Option Exercise3.1825,00079,50055,547May 04
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.